

Table S1 Baseline characteristics in patients attending follow-up vs. not

Variables	Operated (n = 351)			P	Non-operated (n = 91)		P
	All patients n = 442	FU (n = 304) [86.6%]	Not FU (n = 47) [13.4%]		FU (n = 57) [62.6%]	Not FU (n = 34) [37.4%]	
<b>Demography</b>							
Mean age, years	74±11	72±10	76±10	0.021	80±10	83±7	0.197
Male sex – n (%)	249 (56.3)	180 (59.2)	25 (53.2)	0.436	30 (52.6)	14 (41.1)	0.290
Married or partner – n (%)	270 (61.1)	201 (69.8)	22 (47.8)	0.003	33 (64.7)	14 (46.6)	0.112
Body mass index, kg/m <sup>2</sup>	26±5	26±4	26±4	0.284	25±5	25±5	0.851
<b>Medical history – n (%)</b>							
Hypertension	202 (45.7)	142 (46.7)	20 (42.6)	0.595	24 (42.1)	16 (47.1)	0.645
Heart failure	28 (6.3)	12 (4.0)	5 (10.6)	0.047	4 (7.0)	7 (20.6)	0.055
Atrial fibrillation, all types	94 (21.3)	55 (18.1)	10 (21.3)	0.601	11 (19.3)	18 (52.9)	0.001
Diabetes mellitus	48 (10.9)	24 (7.9)	7 (14.9)	0.116	10 (17.5)	1 (20.6)	0.719
Pulmonary disease	77 (17.4)	49 (16.1)	8 (17.0)	0.876	9 (15.8)	11 (32.4)	0.065
Kidney disease	25 (5.7)	10 (3.3)	5 (10.6)	0.020	4 (7.0)	6 (17.6)	0.117
Coronary artery disease	131 (29.6)	87 (28.6)	19 (40.4)	0.101	9 (15.8)	16 (47.1)	0.001
<b>Clinical findings</b>							
Systolic blood pressure, mmHg	143±22	144±22	146±22	0.590	143±23	134±26	0.117

Diastolic blood pressure, mmHg	77±12	78±12	76±11	0.309	74±13	74±12	0.770
-----------------------------------	-------	-------	-------	-------	-------	-------	-------

Heart rate, beats/min	73±13	72±13	76±14	0.076	73±12	76±14	0.395
-----------------------	-------	-------	-------	-------	-------	-------	-------

---

**Medication – n(%)**

Betablocker	206 (46.6)	137 (45.1)	20 (42.6)	0.747	27 (47.4)	22 (64.7)	0.109
ACEi/ARB	178 (40.3)	113 (37.2)	22 (46.8)	0.021	32 (56.1)	11 (32.4)	0.028
Calcium antagonist	89 (20.1)	65 (21.4)	6 (12.8)	0.171	10 (17.5)	8 (23.5)	0.488
Statin	233 (52.7)	162 (53.3)	30 (63.8)	0.177	28 (49.1)	13 (38.2)	0.313
Diuretic	165 (37.3)	87 (28.6)	20 (42.6)	0.053	31 (54.4)	27 (79.4)	0.016
Warfarin	90 (20.4)	51 (16.8)	10 (21.3)	0.449	12 (21.0)	17 (50.0)	0.004
Platelet inhibitor	231 (52.3)	164 (54.0)	26 (55.3)	0.861	29 (50.9)	12 (35.3)	0.148
Digitalis	31 (7.0)	15 (4.9)	4 (8.5)	0.313	3 (5.3)	9 (26.5)	0.004

---

**Charlson comorbidity**

0.005 0.046

**index – n (%)**

0	177 (40.0)	134 (44.1)	16 (34.0)	21 (36.8)	6 (17.7)
1-2	213 (48.2)	149 (49.0)	21 (44.7)	27 (47.4)	16 (47.1)
≥3	52 (11.8)	21 (6.9)	10 (21.3)	9 (15.8)	12 (35.3)

---

**Surgical risk score**

Euro(II)SCORE, median (IQR)	2 (1, 4)	2 (3, 1)	3 (5, 2)	0.0003	3 (6, 2)	7 (11, 4)	0.0003
--------------------------------	----------	----------	----------	--------	----------	-----------	--------

---

**NYHA classification – n**

0.207 0.002

(%)

Class I	48 (11)	18 (5.9)	3 (6.4)	20 (35.1)	7 (20.6)
Class II	205 (46)	158 (52.0)	18 (38.3)	23 (40.4)	6 (17.7)
Class III/IV	189 (43)	128 (42.1)	26 (55.3)	14 (24.6)	21 (61.8)

---

<b>CCS angina score – n (%)</b>				0.712			0.260
Score 0	251 (56.8)	161 (53.0)	25 (53.2)		44 (77.2)	21 (61.7)	
Score 1-2	163 (36.9)	126 (41.5)	18 (38.3)		10 (17.5)	9 (26.5)	
Score 3-4	28 (6.3)	17 (5.6)	4 (8.5)		3 (5.3)	4 (11.8)	
<b>Echocardiographic measures</b>							
SWTd, cm	1.1±0.2	1.1±0.2	1.1±0.2	0.405	1.2±0.2	1.1±0.2	0.295
LVIDd, cm	5.0 ±0.6	5.0±0.6	5.1±0.7	0.827	4.9±0.6	4.9±0.7	0.876
PWTd, cm	0.9 ±0.1	0.9±0.1	0.9±0.2	0.190	0.9±0.1	0.8±0.1	0.034
LVEF, %	56.2±9.2	56.9±8.3	54.0±10.2	0.034	57.0±10.0	51.8±12.5	0.039
Cardiac output, l/min	4.9 ±1.2	5.0±1.2	4.9±1.2	0.656	4.9±1.2	4.2±1.3	0.015
Aortic peak velocity, m/s	4.7 ±0.8	4.7±0.8	4.8±0.8	0.790	4.5±0.7	4.6±0.8	0.796
Aortic mean gradient, mmHg	55±18	56±18	56±19	0.892	50±16	52±21	0.523
Aortic valve area, cm <sup>2</sup>	0.7 ±0.2	0.7±0.2	0.7±0.2	0.263	0.7±0.2	0.6±0.2	0.001
<b>Biochemical values</b>							
Haemoglobin, g/dL	13.6±1.6	13.8±1.5	13.3±1.5	0.028	13.3±1.8	12.8±2.0	0.250
Blood platelets *10 <sup>9</sup>	251±70	253±69	243±58	0.377	256±72	234±90	0.208
hs-CRP, mg/l	5.1±9	4.6±8.4	5.3±6.2	0.586	4.4±7.5	10.5±16.7	0.020
HbA1c, %	5.9±0.8	5.9±0.7	5.9±0.7	0.615	6.0±1.2	6.0±0.6	0.852
Kreatinin, µmol/L	87±29	83±27	97±35	0.002	89±24	99±40	0.130
eGFR, ml/min	74±33	81±33	63±25	0.0006	62±30	52±27	0.118
NT-proBNP, pmol/L	91	65	127	0.003	133	302	0.009
median (IQR)	(33, 234)	(172, 29)	(244, 47)		(389, 49)	(614, 185)	
hs-TnT, ng/mL,	14 (10-25)	11 (21, 10)	14 (25, 10)	0.410	16 (29, 10)	28 (50, 15)	0.004
median (IQR)							

<b>Patient reported outcomes</b>							
Summary PCS	39±11	40±11	35±9	0.003	38±12	31±12	0.010
Summary MCS	50±11	50±11	47±14	0.115	50±13	46±14	0.179
EQ-5D UK Index score	0.72±0.22	0.74±0.21	0.72±0.20	0.623	0.71±0.24	0.55±0.29	0.007
EQ-VAS score	59±22	61±21	55±23	0.097	61±23	48±24	0.012
<b>Six-Minute Walk test, m</b>	446±133	464±124	430±147	0.172	412±144	287±102	0.003
<b>MMSE score</b>	28.1±2.4	28.5±1.6	27.9±2.2	0.022	27.2±3.8	26.6±3.0	0.475

Plus-minus values are means ±SD. P-values for comparison between operated and non-operated patients. FU, followed up; IQR, interquartile range; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; Euro(II)SCORE, European System for Cardiac Operative Risk Evaluation; NYHA, New York Heart Association; CCS, Canadian Cardiovascular Society; SWTd, septal wall thickness at end-diastole; LVIDd, left ventricular internal dimension at end diastole; PWTd, posterior wall thickness at end-diastole; LVEF, left ventricular ejection fraction; hs-CRP, high-sensitive C-reactive protein; eGFR, estimated glomerular filtration rate (Cockcroft-Gault formula); NT-proBNP, N-terminal pro brain natriuretic peptide; hs-TnT, high-sensitive troponin T; PCS, physical component summary; MCS, mental component summary; EQ-5D UK, EuroQol 5 dimensions United Kingdom; EQ-VAS, EuroQol visual analogue scale; MMSE, Mini-mental state examination.